Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Lebanon Sci-Tech Weekly.
Press releases published on May 5, 2025

Sagitec Awarded MainePERS Project for a Modern Pension Administration System
ST. PAUL, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sagitec is proud to announce that it has been awarded the Maine Public Employees Retirement System (MainePERS) project. This achievement is a testament to Sagitec's commitment to adhering to the vision that …

Cerence AI and Code Factory Collaborate to Bring Voice-Powered Interaction to Self-Service Kiosks
BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global leader pioneering conversational AI-powered user experiences, today announced an expanded collaboration with its long-time partner and distributor, …

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
Improvements in subjective and objective measures of efficacy observed at six months persisted for one year in patients with severe vision impairment from inherited retinal degeneration due to mutations in the LCA5 gene Administration of OPGx-LCA5 by …

IDI Integrates with Ping Identity’s PingOne DaVinci to Deliver Powerful Identity Insights Across the Consumer Journey
BOCA RATON, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- Interactive Data, LLC (“IDI”), a red violet company (NASDAQ: RDVT) and leader in identity verification and risk mitigation, today announced a new integration with Ping Identity, a leader in securing …

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025
LAWRENCEVILLE, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. ET on Monday, …

Study Shows Large Improvements in Long COVID Symptoms and Return to Work
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Researchers at the University of Alabama at Birmingham (UAB) have identified what is believed to be the first intervention found in a randomized controlled trial to show large and very large improvements in …

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Monday, May …

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscle …

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress
Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting as Recommended by Leading Independent Proxy Advisory Firms SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today issued the …

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
-Company remains on track for PDUFA target action date of August 31, 2025- -Advisory committee meeting to be held in advance of target action date- SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company …

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …

UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates
UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the …

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1 Mature overall survival data builds on encouraging high response rates with multiple complete …

Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
Ramat Gan, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, today announced that …

Voreifarem Partners with SwfcNrho Exchange to Create a Global New Paradigm for Medical Data Valuation
New York, NY, May 05, 2025 (GLOBE NEWSWIRE) -- Recently, Voreifarem, the world’s first digital health project built on the core architecture of "medical chips + blockchain" (token abbreviation: IER), officially launched on the international mainstream …

BigCommerce Taps Technology Industry Veteran with Strong Record of Innovation as Chief Product Officer
AUSTIN, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- BigCommerce (Nasdaq: BIGC), a leading provider of open, composable commerce solutions for B2C and B2B brands, retailers, manufacturers and distributors, today announced that Vipul Shah has joined the company …

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025 SELARSDI is approved for all indications …

Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
Builds upon Firefly’s recent acceptance into the NVIDIA Connect program Marks next major step toward building a proprietary foundation model of the human brain KENMORE, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “ …

PFMcrypto Launches the Best Free Digital Asset Management Platform in 2025, Attracting Millions Worldwide
New York, May 05, 2025 (GLOBE NEWSWIRE) -- In a year where passive income is more important than ever, PFMcrypto announces the expansion of its free digital asset management platform, now recognized as the most trusted way to earn passive income without …

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
– Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the …